Yes, Madopar (levodopa/benserazide) and rotigotine can be used together in Parkinson's disease
The combination of Madopar and rotigotine is not only safe but is actually a standard treatment approach for Parkinson's disease, particularly in advanced stages. Rotigotine is specifically approved for use in combination with levodopa throughout the course of Parkinson's disease 1, 2.
Evidence Supporting Concurrent Use
Clinical Trial Data
Multiple high-quality studies demonstrate the safety and efficacy of this combination:
Advanced Parkinson's disease trials showed that rotigotine combined with levodopa significantly reduced "off" time and improved motor functioning and activities of daily living compared to levodopa alone 1
Japanese double-blind controlled trials in 420 patients confirmed that rotigotine (up to 16 mg/24h) combined with levodopa was well-tolerated and effective, with no unexpected safety signals 3
Real-world effectiveness studies demonstrated that adding rotigotine to existing levodopa therapy (or switching from levodopa plus another dopamine agonist) led to clinically meaningful improvements in motor function 4
Practical Considerations
Dosing approach:
- Rotigotine can be added to stable levodopa therapy without necessarily adjusting the levodopa dose initially
- In the clinical studies, only 11 patients out of many required levodopa dose changes when rotigotine was added 4
- Mean rotigotine doses ranged from 4.9-6.1 mg/24h when combined with levodopa 4
Age-related factors:
- Both elderly (≥70 years) and younger patients showed similar improvements with the combination, though younger patients may experience slightly greater motor benefits 4, 5
- Elderly patients actually showed similar or lower rates of adverse events compared to younger patients 5
Safety Profile of the Combination
The combination is generally well-tolerated with predictable adverse effects:
- Most common side effects: Application-site reactions (from the patch), gastrointestinal disturbances, somnolence, and headache 1, 2
- Long-term safety: Extension studies up to 6 years showed no unexpected adverse effects 1, 2
- No contraindication: There is no pharmacological contraindication to combining these medications
Clinical Advantages of This Combination
Rotigotine offers specific benefits when combined with levodopa:
- Provides continuous 24-hour dopaminergic stimulation through transdermal delivery 2
- Can be administered even when oral medications are difficult (e.g., swallowing problems, gastrointestinal issues) 2
- May help with early morning motor control and night-time symptoms 1
- Stimulates all dopamine receptors (D1-D5) like endogenous dopamine 5
Important Caveats
Monitor for dopaminergic side effects when using this combination, including:
- Impulse control disorders (though this is a class effect of all dopamine agonists, not specific to the combination) 6
- Excessive daytime somnolence or sudden sleep onset 6
- Hallucinations or confusion, particularly in elderly patients with cognitive impairment 6
Application site reactions occur in approximately 58% of rotigotine patients but are typically manageable by rotating patch sites 3
Avoid abrupt discontinuation of either medication, as this can precipitate parkinsonism-hyperpyrexia syndrome (similar to neuroleptic malignant syndrome) 6, 7